NHS To Roll Out Life-Extending Drug For Advanced Gastroesophageal Cancer
NHS comments on NICE decision to approve Nivolumab to treat rare forms of gastroesophageal cancer after final draft guidance was published today (24 November 2022).
NHS National Cancer Director Professor Peter Johnson said: “Cancer of the oesophagus is one of the most difficult to diagnose and treat and this new life-extending drug, used with chemotherapy, will give hope to thousands of people with this illness, allowing them to spend more time with loved ones, enjoy a better quality of life and in some cases help them become cancer-free.
“It is yet another example of the NHS using its commercial capabilities to deliver cutting-edge drugs, combined with our work to catch cancers earlier than ever before, straight to patients who need them – giving them the best chance of surviving cancer.”
People In This Post
Companies In This Post
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more